BioCardia director granted 8,000 stock options

BioCardia, Inc. director Bill Facteau received a grant of stock options representing the right to buy 8,000 shares of common stock.

Rhea-AI Filing Summary

BioCardia, Inc. director Bill Facteau received a grant of stock options representing the right to buy 8,000 shares of common stock. The options have an exercise price of $1.20 per share and expire on July 6, 2036.

All 8,000 option shares vest and become exercisable on the one-year anniversary of the grant date, as long as he continues as a service provider through that date. After this grant, his directly held option awards total 23,729 underlying shares.

Insider Trade Summary

Grant/Award: 8,000 shares

Grant/Award 1 txn

Insider Facteau Bill

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	8,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 23,729 contracts (Direct)

Footnotes (1)

1. F1. One hundred percent of the shares are subject to the option vesting and becoming exercisable on the one-year anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.

Key Figures

Options granted: 8,000 options Exercise price: $1.20 per share Expiration date: July 6, 2036 +2 more

5 metrics

Options granted 8,000 options Grant for common stock on July 6, 2026

Exercise price $1.20 per share Exercise price of granted stock options

Expiration date July 6, 2036 Option term end date

Post-grant option holdings 23,729 shares Total underlying common shares following transaction

Vesting schedule 100% after one year Vests on one-year anniversary of grant, service-based

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "1.2000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares are subject to the option vesting and becoming exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

service provider financial

"subject to the Reporting Person continuing as a service provider"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioCardia (BCDA) report for Bill Facteau?

BioCardia reported that director Bill Facteau received a grant of stock options for 8,000 underlying common shares. The options were granted at an exercise price of $1.20 per share and represent a compensation-related award, not an open-market stock purchase or sale.

What are the key terms of Bill Facteau’s new BioCardia (BCDA) stock options?

Bill Facteau’s newly granted options cover 8,000 common shares at a $1.20 exercise price and expire on July 6, 2036. These terms define how many shares he can buy, at what price, and the latest date he can exercise the options.

When do Bill Facteau’s BioCardia (BCDA) stock options vest?

All 8,000 option shares vest and become exercisable on the one-year anniversary of the grant date. Vesting is contingent on Facteau continuing as a service provider to BioCardia through that anniversary, aligning the award with his ongoing service to the company.

How many BioCardia (BCDA) option shares does Bill Facteau hold after this grant?

Following the reported grant, Bill Facteau holds stock options representing 23,729 underlying common shares directly. This total includes the newly awarded 8,000 option shares and reflects his aggregate derivative position shown in the Form 4 filing.

Is Bill Facteau’s BioCardia (BCDA) Form 4 transaction a market buy or sell?

The Form 4 shows a grant or award acquisition of options, not a market buy or sell of common stock. The transaction is coded as an “A” for grant, with no open-market purchase or sale of BioCardia shares reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 09:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Facteau Bill

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.2	07/06/2026		A		8,000		(1)	07/06/2036	Common stock	8,000	$0	23,729	D

Explanation of Responses:

1. One hundred percent of the shares are subject to the option vesting and becoming exercisable on the one-year anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.

	/s/ David McClung, by power of attorney	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)